Study title: A PROSPECTIVE, OPEN, SINGLE-CENTER STUDY TO DETERMINE THE SAFETY OF I.V.AND ORAL CIPROFLOXACIN IN THE TREATMENT OF SELECTED PAEDIATRIC INFECTION.(AMENDMENT NO.2/30.JUN.97)
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: CIPROFLOXACIN | |||||
ATC code: J01MA02 | |||||
Document link: Bayer Pharma_Ciprofloxacin_0575_study_synopsis.pdf | |||||
Document date: 2011-09-07 | |||||
Study number: BAY-Q3939-0575 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |